Stock Track | Glaukos Soars 10.29% After-Hours on Strong Q1 Beat and Raised Sales Forecast

Stock Track

Apr 30

Glaukos Corporation's stock experienced a significant after-hours surge of 10.29% following the release of its first-quarter 2026 financial results.

The ophthalmic therapy firm reported quarterly results that exceeded analyst expectations. Adjusted earnings per share came in at a loss of $0.18, beating the consensus estimate of a $0.27 loss. Furthermore, net sales for the quarter rose 41% year-over-year to $150.6 million, surpassing the estimated $136.9 million.

In a key positive development, the company raised its full-year 2026 net sales guidance to a range of $620 million to $635 million, up from the previous forecast of $600 million to $620 million. Management cited products iDose TR and Epioxa as key growth drivers, with the glaucoma segment showing particularly strong performance, including a 58% increase in U.S. glaucoma sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1189432530"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189432530\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189432530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189432530","market":"sg","top_or_hot":-1,"title":"Stock Track | Glaukos Soars 10.29% After-Hours on Strong Q1 Beat and Raised Sales Forecast","media":"Stock Track","content":"<p>Glaukos Corporation's stock experienced a significant after-hours surge of 10.29% following the release of its first-quarter 2026 financial results.</p><p>The ophthalmic therapy firm reported quarterly results that exceeded analyst expectations. Adjusted earnings per share came in at a loss of $0.18, beating the consensus estimate of a $0.27 loss. Furthermore, net sales for the quarter rose 41% year-over-year to $150.6 million, surpassing the estimated $136.9 million.</p><p>In a key positive development, the company raised its full-year 2026 net sales guidance to a range of $620 million to $635 million, up from the previous forecast of $600 million to $620 million. Management cited products iDose TR and Epioxa as key growth drivers, with the glaucoma segment showing particularly strong performance, including a 58% increase in U.S. glaucoma sales.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Glaukos Soars 10.29% After-Hours on Strong Q1 Beat and Raised Sales Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Glaukos Soars 10.29% After-Hours on Strong Q1 Beat and Raised Sales Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-30 05:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaukos Corporation's stock experienced a significant after-hours surge of 10.29% following the release of its first-quarter 2026 financial results.</p><p>The ophthalmic therapy firm reported quarterly results that exceeded analyst expectations. Adjusted earnings per share came in at a loss of $0.18, beating the consensus estimate of a $0.27 loss. Furthermore, net sales for the quarter rose 41% year-over-year to $150.6 million, surpassing the estimated $136.9 million.</p><p>In a key positive development, the company raised its full-year 2026 net sales guidance to a range of $620 million to $635 million, up from the previous forecast of $600 million to $620 million. Management cited products iDose TR and Epioxa as key growth drivers, with the glaucoma segment showing particularly strong performance, including a 58% increase in U.S. glaucoma sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GKOS","symbol_name":"Glaukos Corp","start_time":0,"source_url":"","article_id":"1189432530","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189432530","pubTimestamp":1777496812,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Glaukos Corporation's stock experienced a significant after-hours surge of 10.29% following the release of its first-quarter 2026 financial results.The ophthalmic therapy firm reported quarterly...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GKOS":"Glaukos Corp"},"translate_title":"个股追踪|Glaukos盘后大涨10.29%，Q1表现强劲，销售预期上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":1},"content_text":"Glaukos Corporation's stock experienced a significant after-hours surge of 10.29% following the release of its first-quarter 2026 financial results.The ophthalmic therapy firm reported quarterly results that exceeded analyst expectations. Adjusted earnings per share came in at a loss of $0.18, beating the consensus estimate of a $0.27 loss. Furthermore, net sales for the quarter rose 41% year-over-year to $150.6 million, surpassing the estimated $136.9 million.In a key positive development, the company raised its full-year 2026 net sales guidance to a range of $620 million to $635 million, up from the previous forecast of $600 million to $620 million. Management cited products iDose TR and Epioxa as key growth drivers, with the glaucoma segment showing particularly strong performance, including a 58% increase in U.S. glaucoma sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}